Literature DB >> 25594074

Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?

Troy T Rohn1, Katie L McCarty2, Julia E Love, Elizabeth Head.   

Abstract

Down syndrome is one of the most common genetic causes of intellectual disability and is characterized by a number of behavioral as well as cognitive symptoms. Triplication of all or part of human chromosome 21 has been considered as the main cause of Down syndrome. Due to the location of the amyloid precursor protein on chromosome 21, many of the neuropathological features of early-onset Alzheimer's disease including senile plaques and neurofibrillary tangles are also present in Down syndrome patients who are either demented or nondemented. Significant advances in medical treatment have increased longevity in people with Down syndrome resulting in an increased population that may be subjected to many of the same risk factors as those with Alzheimer's disease. It is well established that harboring one or both apolipoprotein E4 alleles greatly increases the risk for Alzheimer's disease. However, whether apolipoprotein E4 contributes to an earlier onset of dementia or increased mortality in Down syndrome patients is still a matter of debate. The purpose of this mini review is to provide an updated assessment on apolipoprotein E4 status and risk potential of developing dementia and mortality associated with Down syndrome.

Entities:  

Keywords:  Alzheimer’s disease; Apolipoprotein E4 (ApoE4); Beta-amyloid; Down syndrome; Mortality; Neurofibrillary tangles; Pathology; Risk factors; Senile plaques

Year:  2014        PMID: 25594074      PMCID: PMC4291017          DOI: 10.13188/2376-922x.1000004

Source DB:  PubMed          Journal:  J Parkinsons Dis Alzheimers Dis        ISSN: 2376-922X


  74 in total

Review 1.  Genetic and host factors for dementia in Down's syndrome.

Authors:  Nicole Schupf; Gertrude H Sergievsky
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

Review 2.  Down syndrome and beta-amyloid deposition.

Authors:  Elizabeth Head; Ira T Lott
Journal:  Curr Opin Neurol       Date:  2004-04       Impact factor: 5.710

Review 3.  Dementia and mortality in persons with Down's syndrome.

Authors:  A Coppus; H Evenhuis; G-J Verberne; F Visser; P van Gool; P Eikelenboom; C van Duijin
Journal:  J Intellect Disabil Res       Date:  2006-10

4.  Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.

Authors:  K H Weisgraber; S C Rall; R W Mahley
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

5.  Longitudinal study of thyroid function in Down's syndrome in the first two decades.

Authors:  P A Gibson; R W Newton; K Selby; D A Price; K Leyland; G M Addison
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

6.  Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals.

Authors:  Karen H Gylys; Jeffrey A Fein; Aiko M Tan; Gregory M Cole
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

7.  A comparison between older persons with down syndrome and a control group: clinical characteristics, functional status and sensorimotor function.

Authors:  Eli Carmeli; Shlomo Kessel; Shmuel Bar-Chad; Joav Merrick
Journal:  Downs Syndr Res Pract       Date:  2004-06

8.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

9.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

10.  Differences in age-related effects on brain volume in Down syndrome as compared to Williams syndrome and typical development.

Authors:  Mary Ellen I Koran; Timothy J Hohman; Courtney M Edwards; Jennifer N Vega; Jennifer R Pryweller; Laura E Slosky; Genea Crockett; Lynette Villa de Rey; Shashwath A Meda; Nathan Dankner; Suzanne N Avery; Jennifer U Blackford; Elisabeth M Dykens; Tricia A Thornton-Wells
Journal:  J Neurodev Disord       Date:  2014-04-09       Impact factor: 4.025

View more
  11 in total

1.  Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

Authors:  Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B.

Authors:  Patrick J Lao; Tobey J Betthauser; Ansel T Hillmer; Julie C Price; William E Klunk; Iulia Mihaila; Andrew T Higgins; Peter D Bulova; Sigan L Hartley; Regina Hardison; Rameshwari V Tumuluru; Dhanabalan Murali; Chester A Mathis; Annie D Cohen; Todd E Barnhart; Darlynne A Devenny; Marsha R Mailick; Sterling C Johnson; Benjamin L Handen; Bradley T Christian
Journal:  Alzheimers Dement       Date:  2015-06-13       Impact factor: 21.566

3.  Resting-State Functional Connectivity in Individuals with Down Syndrome and Williams Syndrome Compared with Typically Developing Controls.

Authors:  Jennifer N Vega; Timothy J Hohman; Jennifer R Pryweller; Elisabeth M Dykens; Tricia A Thornton-Wells
Journal:  Brain Connect       Date:  2015-04-28

Review 4.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

Review 5.  Down syndrome.

Authors:  Stylianos E Antonarakis; Brian G Skotko; Michael S Rafii; Andre Strydom; Sarah E Pape; Diana W Bianchi; Stephanie L Sherman; Roger H Reeves
Journal:  Nat Rev Dis Primers       Date:  2020-02-06       Impact factor: 52.329

Review 6.  Pharmacological interventions for cognitive decline in people with Down syndrome.

Authors:  Nuala Livingstone; Jennifer Hanratty; Rupert McShane; Geraldine Macdonald
Journal:  Cochrane Database Syst Rev       Date:  2015-10-29

7.  Proteolytic Cleavage of Apolipoprotein E in the Down Syndrome Brain.

Authors:  Ryan J Day; Katie L McCarty; Kayla E Ockerse; Elizabeth Head; Troy T Rohn
Journal:  Aging Dis       Date:  2016-05-27       Impact factor: 6.745

Review 8.  A critical literature review of the effectiveness of various instruments in the diagnosis of dementia in adults with intellectual disabilities.

Authors:  Jordan Elliott-King; Sarah Shaw; Stephan Bandelow; Rajal Devshi; Shelina Kassam; Eef Hogervorst
Journal:  Alzheimers Dement (Amst)       Date:  2016-06-30

9.  Age-Related Decrease in Heat Shock 70-kDa Protein 8 in Cerebrospinal Fluid Is Associated with Increased Oxidative Stress.

Authors:  David A Loeffler; Andrea C Klaver; Mary P Coffey; Jan O Aasly; Peter A LeWitt
Journal:  Front Aging Neurosci       Date:  2016-07-26       Impact factor: 5.750

10.  Olfaction in People with Down Syndrome: A Comprehensive Assessment across Four Decades of Age.

Authors:  Maria Paola Cecchini; Dario Viviani; Marco Sandri; Antje Hähner; Thomas Hummel; Carlo Zancanaro
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.